The Neo-Antigen Biotechnology (NEO-AG) Ltd. is an emerging biotechnology company focused on transforming immunization strategies through advanced epitope-based vaccine technologies. The company’s core innovation lies in its proprietary TFR123 platform, which represents a novel approach to addressing one of the most fundamental challenges in immunology: the invisibility of pathogens and cancer cells to the human immune system. By leveraging targeted epitopes, NEO-AG aims to create a new generation of vaccines and immunotherapies capable of improving both prevention and treatment outcomes.The company’s approach is based on recognizing that both pathogens and tumors survive by remaining “invisible” to host’s immune system. NEO-AG aims to make these hidden threats detectable by directing the immune system toward precise molecular targets. This shifts immunization from general immune activation to a more precise, targeted identification strategy, especially through nucleic acid-based vaccines. The TFR123 platform uses short, carefully selected epitopes to enhance immune recognition. Unlike traditional vaccines, it focuses on key molecular fragments that trigger strong responses. As a result, even weakly immunogenic targets become visible and actionable for the immune system, enabling more efficient, targeted, and potentially personalized immunotherapy solutions.One of the major strengths of the TFR123 platform is its versatility. The technology is designed to be applicable across multiple domains, including infectious diseases, oncology, and targeted drug delivery. This broad applicability not only enhances the scientific value of the platform but also significantly increases its commercial potential.